Highest development stage: Preclinical

Development dropped

Gram-negative activity

Mechanism of Action/Target pathogen: Active against S. aureus both oxacillin susecptible and resistant strains

Reason dropped: Literature papers stop at 1992 which concludes with a need to carry out more pharmacological studies to progress to clinical trials. The study on PMN activity shows that for interference, a dosage higher than proposed human dosage is required. There may be a cross resistance issue but not stated.

Additional information: Teicoplanin derivative